)
)
)
Resolution Therapeutics is a clinical stage pioneer in Regenerative Macrophage Therapies (RMT) for Inflammatory and Fibrotic Diseases. CLINICAL PROGRAM / HIGH UNMET NEED - EMERALD/OPAL (P1/2) for End Stage Liver Disease (ESLD), which affects >500k people in the US with liver transplantation as the only option, leaving over 90% of patients with no alternative. TRANSFORMATIVE TREATMENT - Engineered macrophages with enhanced anti-inflammatory and anti-fibrotic efficacy, optimised by payload ROBUST SCIENCE & CLINICAL EVIDENCE - Two clinical Proof of Concept studies demonstrating safety and efficacy in patients with cirrhosis; robust biomarker package FOCUSED PIPELINE - Efficacy demonstrated in lung fibrosis and GvHD with platform expansion into In Vivo modality
Year Founded
2020
Next catalyst (value inflection) update
EMERALD/OPAL - Interim data readout
Expected time of next catalyst update
Jul-26
City
London
Country
United Kingdom
Company CEO or top company official
Dr Amir Hefni
Development Phase of Primary Product
Phase II
Lead Product in Development
EMERALD/OPAL - RTX001 for decompensated cirrhosis
Therapeutic Area
Gene/Cell Therapy
Website
https://resolution-tx.com/
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
